Popular Trials
Topoisomerase I inhibitors
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
Recruiting2 awardsPhase 1
Houston, Texas
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
Checkpoint Inhibitor
Nivolumab + Ipilimumab for Thyroid Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing two drugs, nivolumab and ipilimumab, to see if they can help treat thyroid cancer by boosting the immune system to fight cancer cells. These drugs have shown promising results in treating various cancers by enhancing the immune system's response to tumors.
PD-L1 Inhibitor
RAI + Immunotherapy for Thyroid Cancer
Recruiting1 awardPhase < 1
Basking Ridge, New Jersey
This trial is testing a new drug, durvalumab, to see if it can help treat thyroid cancer. Durvalumab blocks a protein that can be present on tumor and normal cells, which may help the immune system fight the cancer.
Alkylating agents
Cyclophosphamide + Sirolimus for Advanced Thyroid Cancer
Recruiting1 awardPhase 2
Ann Arbor, Michigan
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Popular Filters
Trials for Thyroid Gland Carcinoma Patients
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Trials for Thyroid Nodule Patients
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Trials for Metastatic Patients
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Trials for BRAF Positive Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Chemotherapy
Atezolizumab + Chemotherapy for Thyroid Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing a combination of atezolizumab and chemotherapy in patients with aggressive thyroid cancer. The treatment aims to boost the immune system and stop cancer cell growth. Atezolizumab helps enhance the immune response against cancer cells.
MEK Inhibitor
Selumetinib + Olaparib for Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial has two phases: in the first, they'll find the highest dose of the drugs that patients can tolerate; in the second, they'll see if that dose can help control patients' advanced or recurrent solid tumors. Safety will also be monitored in both phases.
Checkpoint Inhibitor
Encorafenib + Binimetinib +/- Nivolumab for Thyroid Cancer
Recruiting1 awardPhase 2
Portland, Oregon
This trial studies how well encorafenib and binimetinib, with or without nivolumab, work in treating a specific type of thyroid cancer that has spread and doesn't respond to usual treatments. The drugs aim to stop cancer growth and help the immune system fight the cancer. Encorafenib and binimetinib are used in combination to treat BRAF V600 mutation-positive melanoma, showing improved response rates and survival.
Kinase Inhibitor
Dabrafenib + Trametinib + IMRT for Thyroid Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is testing whether combining dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) is more effective at treating patients with BRAF mutated anaplastic thyroid cancer than just using IMRT alone.
Trials for RET Positive Patients
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
Tyrosine Kinase Inhibitor
Selpercatinib for Thyroid Cancer
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial is looking at a new treatment option for patients with advanced papillary thyroid cancer after surgery. The current treatment, radioactive iodine therapy, is not always effective and has potential risks such as lung
Trials With No Placebo
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
MEK Inhibitor
Trametinib for Thyroid Cancer
Recruiting1 awardPhase 2
New York, New York
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.